48
Participants
Start Date
December 3, 2022
Primary Completion Date
January 13, 2024
Study Completion Date
January 13, 2024
RO7223280
Participants will receive RO7223280, 600 mg, IV infusion for 1 hour on Day 1.
RO7223280
Participants will receive RO7223280, 400 mg, IV infusion for 1 hour on Day 1.
Asan Medical Center., Seoul
Infectious Disease Associates, Sarasota
University of Louisville Physicians, Louisville
Beaumont Hospital; Royal Oak Pharmacy, Royal Oak
Centre Hospitalier Régional Universitaire de Lille, Lille
Hôpitaux Universitaires de strasbourg - hôpital civil, Strasbourg
Groupe Hospitalier Bichat Claude Bernard, Paris
Hôpital Saint-Louis, Paris
CHU de Limoges - Hôpital Dupuytren, Limoges
Oregon Health & Science University, Portland
The Chaim Sheba Medical Center; Multiple Sclerosis Center, Ramat Gan
Tel-Aviv Sourasky Medical Center, Tel Aviv
Hadassah Ein Karem Hospital, Jerusalem
East Carolina University (ECU) Physicians - Infectious Disease Clinic - Greenville, Greenville
ARENSIA Phase 1 Unit- Spitalul Clinic Republican Location, Chisinau
Hallym University Kangnam Sacred Heart Hospital, Seoul
Hoffmann-La Roche
INDUSTRY